All newly approved drugs will default to non-preferred status until a full clinical review by the national pharmacy and therap
CIGNA Drug List Changes – Third Quarter 2009 CIGNA periodically reviews its drug list to promote continued effectiveness. Based on that review, the following
changes have been made to the CIGNA drug list from July 1, 2009 to September 30, 2009. Drugs marked with an (*), or (~) indicate that prior authorization, or step therapy is required, respectively. Note: This list includes selected brand and generic drug changes and is subject to change. CIGNA does not take responsibility for any medication decisions made by prescriber and pharmacist. Selected New Generic Drugs Added to Drug List Reference Brand Name Generic Name
__________________________________________________________________________________________ Benzaclin
Fibricor~ Selected New Preferred Drugs Added to Drug List Reference __________________________________________________________________________________________ Analpram Selected Non-Preferred Brands Switched to Preferred Brands Brand Name Generic Name
__________________________________________________________________________________________
* Prior Authorization ~Step Therapy CIGNA Drug List Changes – Third Quarter 2009 Selected Preferred Brands Switched to Non-Preferred Brands Brand Name Generic Name
__________________________________________________________________________________________
chlorpheniramine/methscopolamine/phenylephrine
phenylephrine/chlorpheniramine/methscopolamine
guaifenesin/theophylline/pseudoephedrine
Capital W/Codeine codeine/acetaminophen Colymycins S
Cortisporin (ointment) neomycin/bacitracin/polymyxin/hydrocortisone
Cortisporin (cream) neomycin/polymyxin/hydrocortisone
chlorpheniramine/methscopolamine/phenylephrine
Depo-Testosterone* testosterone cypionate
phenylephrine/chlorpheniramine/methscopolamine
Synalgos-DC dihydrocodeine/aspirin/caffeine Syprine
CIGNA Drug List Changes – Third Quarter 2009 Selected Preferred Brands Switched to Non-Preferred Brands (continued) Brand Name Generic Name
__________________________________________________________________________________________
brompheniramine/dextromethorphan/guaifenesin
Tusnel Pediatric guaifenesin/pseudoephedrine
Tusnel Pediatric brompheniramine/dextromethorphan/guaifenesin Tyzine
Brand Drugs at Highest Copay with other Brand / Generic Alternatives Brand Name Generic Name
__________________________________________________________________________________________
Selected New Brand Drugs Added as Non-Preferred Brands1 Brand Name Generic Name
_________________________________________________________________________________________ Acuvail
Adcirca*
Bepreve bepotastine Edluar~
Embeda morphine/naltrexone Fibricor~
Onglyza~ 1All newly approved "priority" drugs and "non-priority" drugs as designated by the Food and Drug Administration ["FDA"] will default to non-preferred status until review by the CIGNA Pharmacy and Therapeutics Committee (P&T Committee). The P&T Committee reviews priority drugs within six months of FDA approval of the drug. * Prior Authorization ~Step Therapy CIGNA Drug List Changes – Third Quarter 2009 Removal of Step Therapy from Selected Drugs Brand Name Generic Name
____________________________________________________________________________________
Drug Recalls Removed from Drug List Brand Name Generic Name
____________________________________________________________________________________
CIGNA,” “CIGNA HealthCare,” “CIGNA Pharmacy Management” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, Tel-Drug, Inc. and its affiliates, CIGNA Behavioral Health, Inc., Intracorp, and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company.
Study supports traditional diabetes therapy claim A clinical trial by researchers at The University of Auckland’s Liggins Institute has shown that an extract of fresh olive leaves appreciably reduces some risk factors for developing type 2 diabetes. A paper published today in the peer-reviewed journal PLOS ONE presents results of the randomized, double-blinded, placebo-controlled, crossove
– Allez Edison, c’est l’heure ! Et pas de blagues cette fois, si tu mords encore les fesses de monsieur Pois pendant le cours, plus de Questions pour un Champion pendant un Edison partit se cacher sous le bureau de son maître avant même que celui-ci ait terminé sa phrase. Edison adorait la télé en général, et Julien Lepers en particulier. Fait rare chez un chien, certes, mai